September 29, 2017
Eli Lilly in leadership chances
Eli Lilly has made certain leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
September 29, 2017
IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes
To mark World Heart Day, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes.
September 29, 2017
FDA OK’s Eli Lilly’s breast cancer drug
The U.S. Food and Drug Administration has approved Eli Lilly’s Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).
September 28, 2017
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”
September 28, 2017
Basilea Pharmaceutica in license agreement with Chinese drugmaker
Basilea Pharmaceutica has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea’s antibiotic Zevtera (ceftobiprole) in China, Hong Kong and Macao (the Territory).
September 28, 2017
European Comission OKs Sanogi’s, Regeneron’s dermatitis treatment Dupixent
Sanofi and Regeneron Pharmaceuticals got European Commission marketing authorization for Dupixent for use in adults with moderate-to-severe atopic dermatitis (AD)…
September 27, 2017
Novo Nordisk’s diabetes drug in China
China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.
September 27, 2017
Federal judge orders U.S. company to stop distributing unapproved drugs
FDA has reported that the federal judge ordered a New Jersey company that sold injectable skin whitening and other beauty products to stop selling and recall some of its products because they are unapproved new drugs that may be unsafe, putting consumers at risk.
September 26, 2017
Domestic companies predict a 16% growth in the South Korean pharma market during CPhI Korea
CPhI Korea, organized by UBM, closed its doors in Seoul after another record-breaking event that attracted 4,300 attendees and 147…
September 26, 2017
ADC Bio to invest $11m on Bioconjugation facility
ADC Biotechnology has secured investment for the construction of a bioconjugation facility at its new site in Deeside, North Wales,…